Table 1 Clinical characteristics of ASXL1+ AML
From: Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia
Characteristics | Median (interquartile range) or N (%) |
|---|---|
Gender male (n [%]) | 49 (54%) |
Age (years) | 50 (33–58) |
Age ≥ 60 years (n [%]) | 20 (22%) |
Type (APL vs. non-APL) | 4 (4%) |
ASXL1 type (n [%]) | |
 G652S | 38 (41.76%) |
 G642fs | 11 (12.09%) |
 H630fs | 8 (8.79%) |
 ASXL1 VAF(%) | 49.17 (22.9–57.11) |
 ASXL1 VAF (≥49.17%) | 46 (51%) |
 WBC counts (× 109/L) | 7.5 (2.4–33.3) |
 WBC counts (≥50 × 109/L) | 18 (19.78%) |
 HGB counts (g/L) | 79 (66–93) |
 HGB counts (≥110 g/L) | 13 (14%) |
 PLT counts ( × 109/L) | 48 (20–93) |
 PLT counts (≥100 × 109/L) | 19 (21%) |
 Bone marrow blasts (%) | 51 (26–72) |
 Bone marrow blasts (≥80%) | 15 (16%) |
 AML1-ETO | 17 (19%) |
 CBFβ-MYH11 | 3 (3%) |
Risk group | |
 Favorable | 27 (30%) |
 Intermediate | 1 (1%) |
 Adverse | 63 (69%) |